Effects of nanocapsules containing all-trans-retinoic acid under hemolytic and coagulation activity

Abstract

The chemotherapeutic all-trans retinoic acid (ATRA) used in the treatment of Acute Promyelocytic Leukemia has adverse effects on its oral administration, with which we incorporated a system of drugs, the nanocapsules, in order to have a possible improvement in solubility, photosensitivity, lower toxicity, generating pharmacological efficacy. The objective was to evaluate and compare the hemolytic and coagulation activity of the free drug (AL), nanoencapsulated (NA) and the white nanocapsules (NB) by analyzing the results of hemolysis, Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT). We developed a prospective study of treatments at different concentrations of 0.25; 0.5; 1.0; 1.5; 2.0; 2.5 μg/mL. For the first test, all concentrations showed hemolytic activity, but when compared to NA with ATRA it is observed that these carriers induced lower hemolytic toxicity. In the PT test the nanoparticles at the two lowest concentrations remained in the physiological range (12 - 15 seconds). For the APTT test the three lowest concentrations remained within the control (25 - 35 seconds). Thus, we believe there is a promising benefit of using these nanoparticles developed and no doubt further studies will be performed to confirm the responses obtained here.

Phytochemical Characterization, Pharmacological Properties And Toxicity of Amazonian Fruit Cubiu (Solanum Sessiliflorum Dunal)

“…Hemocompatibility tests were performed according to Souza Filho et al 15 . Blood was added with a phosphate-buffered saline (PBS) 1X solution (1:1 v/v) and centrifuged for 15 min at 1000 rpm, and the supernatant was discarded (procedure performed three times).…”

“…The coagulation test was carried out according to Souza Filho et al 15 . Total blood levels were collected in a citrate tube and centrifuged for 10 min at 2500 rpm.…”